Aroa Biosurgery Management
Management Kriterienprüfungen 3/4
Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.
Wichtige Informationen
Brian Ward
Geschäftsführender
NZ$1.7m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 33.03% |
| Amtszeit als Geschäftsführer | 18.8yrs |
| Eigentum des Geschäftsführers | 9.6% |
| Durchschnittliche Amtszeit des Managements | 6yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 6.7yrs |
Jüngste Management Updates
Recent updates
Narrative-Update • Jul 06
ARX: Higher Multiple And Earnings Outlook Will Support Future Upside
Analysts have lifted their Aroa Biosurgery price target from A$1.16 to A$1.35, citing updated assumptions around discount rates, revenue growth, profit margins, and a higher future P/E multiple in their valuation work. What's in the News Aroa Biosurgery issued earnings guidance for fiscal 2026, indicating expected total revenue of approximately NZ$104 million on an actual basis, according to company guidance.
Narrative-Update • Jun 22
ARX: Positive Trial Success And Growing Portfolio Will Support Future Earnings Power
Analysts have maintained their Aroa Biosurgery fair value estimate at A$1.09. They applied a slightly higher discount rate and made only minor adjustments to revenue growth, profit margin and future P/E assumptions to support their unchanged price target view.Narrative-Update • Jun 05
ARX: Positive Trial Results Will Underpin Future Earnings Power
Analysts have nudged their price target for Aroa Biosurgery higher to A$1.09 from A$1.07, reflecting updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News Aroa Biosurgery issued earnings guidance for fiscal 2026, projecting total revenue of about NZ$104 million on an actual basis, citing stronger than expected sales in the Myriad portfolio and favourable foreign exchange movements.Narrative-Update • May 03
ARX: Positive Wound Trial Results Will Support Stronger Future Profitability
Analysts have lifted their price target for Aroa Biosurgery from A$0.83 to A$1.07, citing updated assumptions that include a higher discount rate, a slightly adjusted revenue growth outlook, a stronger forecast profit margin, and a lower future P/E multiple. What's in the News Aroa Biosurgery reported completion of its randomised controlled trial of Symphony, a skin substitute designed for hard to heal wounds such as diabetic foot ulcers and venous leg ulcers, with a preliminary read out indicating the primary endpoint was achieved (Key Developments).
Neues Narrative • Apr 08
Reimbursement Shifts And Partner Dependence Will Reshape Tissue Regeneration Prospects Over Time
Catalysts About Aroa Biosurgery Aroa Biosurgery develops and supplies biologically derived soft tissue regeneration products used in wound care, reconstruction and surgical procedures. What are the underlying business or industry changes driving this perspective?Neues Narrative • Mar 24
Outpatient Expansion And Surgical Partnerships Will Transform Long Term Prospects For This Biologics Supplier
Catalysts About Aroa Biosurgery Aroa Biosurgery develops and supplies biologically derived soft tissue regeneration products used in wound care, trauma, burns and reconstructive surgery. What are the underlying business or industry changes driving this perspective?Analyseartikel • Nov 28
Aroa Biosurgery Limited (ASX:ARX) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?
Aroa Biosurgery Limited ( ASX:ARX ) last week reported its latest half-yearly results, which makes it a good time for...
Neues Narrative • Apr 26
Lebanon, Vietnam, And Saudi Arabia Approvals Will Secure Market Presence
Expansion into international markets and positive clinical outcomes suggest potential revenue growth as new regions adopt Aroa's cost-effective products.Analyseartikel • Apr 07
Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 26% Share Price Plunge
Unfortunately for some shareholders, the Aroa Biosurgery Limited ( ASX:ARX ) share price has dived 26% in the last...Analyseartikel • Mar 24
Aroa Biosurgery (ASX:ARX) Is In A Strong Position To Grow Its Business
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Analyseartikel • Feb 15
Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 26% Share Price Plunge
Aroa Biosurgery Limited ( ASX:ARX ) shareholders won't be pleased to see that the share price has had a very rough...Analyseartikel • Dec 04
Aroa Biosurgery Limited (ASX:ARX) Held Back By Insufficient Growth Even After Shares Climb 26%
Aroa Biosurgery Limited ( ASX:ARX ) shares have continued their recent momentum with a 26% gain in the last month...Analyseartikel • Nov 27
The Aroa Biosurgery Limited (ASX:ARX) Interim Results Are Out And Analysts Have Published New Forecasts
It's been a good week for Aroa Biosurgery Limited ( ASX:ARX ) shareholders, because the company has just released its...Analyseartikel • Nov 13
We're Not Worried About Aroa Biosurgery's (ASX:ARX) Cash Burn
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analyseartikel • Aug 22
Take Care Before Jumping Onto Aroa Biosurgery Limited (ASX:ARX) Even Though It's 29% Cheaper
Aroa Biosurgery Limited ( ASX:ARX ) shareholders won't be pleased to see that the share price has had a very rough...Analyseartikel • Jun 12
Investors Aren't Entirely Convinced By Aroa Biosurgery Limited's (ASX:ARX) Revenues
With a price-to-sales (or "P/S") ratio of 3.3x Aroa Biosurgery Limited ( ASX:ARX ) may be sending very bullish signals...Analyseartikel • Mar 25
Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analyseartikel • Jan 30
Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 25% Share Price Plunge
Aroa Biosurgery Limited ( ASX:ARX ) shareholders that were waiting for something to happen have been dealt a blow with...Analyseartikel • Nov 14
Aroa Biosurgery Limited's (ASX:ARX) Revenues Are Not Doing Enough For Some Investors
With a price-to-sales (or "P/S") ratio of 4.3x Aroa Biosurgery Limited ( ASX:ARX ) may be sending very bullish signals...Analyseartikel • Nov 02
Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts
Shareholders in Aroa Biosurgery Limited ( ASX:ARX ) may be thrilled to learn that the analysts have just delivered a...Analyseartikel • Oct 25
Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price
Does the October share price for Aroa Biosurgery Limited ( ASX:ARX ) reflect what it's really worth? Today, we will...Analyseartikel • May 13
We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2026 | NZ$2m | NZ$574k | NZ$5m |
| Dec 31 2025 | n/a | n/a | NZ$1m |
| Sep 30 2025 | n/a | n/a | -NZ$2m |
| Jun 30 2025 | n/a | n/a | -NZ$3m |
| Mar 31 2025 | NZ$978k | NZ$569k | -NZ$4m |
| Dec 31 2024 | n/a | n/a | -NZ$6m |
| Sep 30 2024 | n/a | n/a | -NZ$8m |
| Jun 30 2024 | n/a | n/a | -NZ$9m |
| Mar 31 2024 | NZ$1m | NZ$583k | -NZ$11m |
| Dec 31 2023 | n/a | n/a | -NZ$9m |
| Sep 30 2023 | n/a | n/a | -NZ$8m |
| Jun 30 2023 | n/a | n/a | -NZ$4m |
| Mar 31 2023 | NZ$1m | NZ$552k | -NZ$396k |
| Dec 31 2022 | n/a | n/a | -NZ$1m |
| Sep 30 2022 | n/a | n/a | -NZ$2m |
| Jun 30 2022 | n/a | n/a | -NZ$5m |
| Mar 31 2022 | NZ$1m | NZ$542k | -NZ$8m |
| Dec 31 2021 | n/a | n/a | -NZ$10m |
| Sep 30 2021 | n/a | n/a | -NZ$11m |
| Jun 30 2021 | n/a | n/a | -NZ$15m |
| Mar 31 2021 | NZ$2m | NZ$483k | -NZ$19m |
Vergütung im Vergleich zum Markt: BrianDie Gesamtvergütung ($USD1.02M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Australian ($USD322.19K).
Entschädigung vs. Einkommen: BrianDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
Geschäftsführer
Brian Ward
18.8yrs
Amtszeit
NZ$1,739,168
Vergütung
Dr. Brian Ward, B.V.Sc, MBA(dist) has been Executive Director at Aroa Biosurgery Limited since September 21, 2007 and serves as its Managing Director and Chief Executive Officer. He has founded Aroa Biosur...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Founder | no data | NZ$1.74m | 9.58% A$ 18.6m | |
| CFO & Joint Company Secretary | 6.4yrs | NZ$627.01k | keine Daten | |
| Chief Operating Officer | no data | keine Daten | keine Daten | |
| Chief of Technical Operations | no data | keine Daten | keine Daten | |
| Chief Scientific Officer | 4.6yrs | keine Daten | 0.95% A$ 1.8m | |
| Joint Company Secretary | 6yrs | keine Daten | keine Daten | |
| Vice President of Medical Affairs | no data | keine Daten | keine Daten | |
| Media Executive | no data | keine Daten | keine Daten |
6.0yrs
Durchschnittliche Betriebszugehörigkeit
Erfahrenes Management: Das Managementteam von ARX ist erfahren und erfahren (durchschnittliche Amtszeit von 6 Jahren).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Founder | 18.8yrs | NZ$1.74m | 9.58% A$ 18.6m | |
| Independent Non-Executive Director | less than a year | NZ$33.33k | 0.14% A$ 280.0k | |
| Independent Non-Executive Chairperson | 14.9yrs | NZ$151.37k | 0.82% A$ 1.6m | |
| Independent Non-Executive Director | 6.7yrs | NZ$123.31k | 0.24% A$ 466.2k | |
| Non-Executive Director | 18.3yrs | NZ$90.91k | 5.8% A$ 11.2m | |
| Independent Non-Executive Director | 3.7yrs | NZ$154.66k | 0.13% A$ 244.4k | |
| Independent Non-Executive Director | 2.3yrs | NZ$155.99k | 0.041% A$ 78.5k |
6.7yrs
Durchschnittliche Betriebszugehörigkeit
Erfahrener Vorstand: ARXDie Vorstandsmitglieder gelten als erfahren (6.7 Jahre durchschnittliche Amtszeit).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/21 16:57 |
| Aktienkurs zum Tagesende | 2026/07/21 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2026/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Aroa Biosurgery Limited wird von 4 Analysten beobachtet. 3 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| John Hester | Bell Potter |
| Shane Storey | Canaccord Genuity |
| Scott Power | Morgans Financial Limited |